Episode 27 of Quantum Computing Business with Fexingo. Lucas and Luna explore how quantum computing is reshaping pharmaceutical R&D contracts. They focus on a recent 2026 deal between Roche and a quantum startup, where milestone payments are tied to quantum-classical hybrid simulation accuracy. The hosts break down why large pharma is moving from exploratory grants to performance-based contracts, how error mitigation techniques affect deliverables, and what this shift means for quantum startups' revenue models. Specific numbers: $450 million potential deal value, 12-month milestones, and 3-year exclusivity clauses. A concrete look at enterprise quantum adoption through the lens of contract law and drug discovery timelines.

#QuantumComputing #DrugDiscovery #Pharma #Roche #QuantumStartup #HybridQuantum #MilestonePayments #ErrorMitigation #R&DContracts #EnterpriseQuantum #BusinessAndTech #FexingoBusiness #BusinessPodcast #QuantumBusiness #PharmaTech #QuantumSimulation #MolecularModeling #ContractLaw

Keep every episode free: buymeacoffee.com/fexingo